Comparative Pharmacology
Head-to-head clinical analysis: EOHILIA versus STIE CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EOHILIA versus STIE CORT.
EOHILIA vs STIE-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Glucocorticoid receptor agonist; modulates gene expression leading to anti-inflammatory and immunosuppressive effects.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
Topical: Apply a thin film to affected area twice daily. Maximum 2-week continuous use. In severe cases, apply up to 4 times daily. Do not exceed 50 g/week.
None Documented
None Documented
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Terminal elimination half-life is 1.5-2 hours (intravenous) and 2-3 hours (oral), reflecting rapid clearance; clinical context: supports twice-daily dosing for systemic effects.
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Renal: 60-70% as metabolites; biliary/fecal: 20-30% as metabolites; unchanged drug: <5%.
Category C
Category C
Corticosteroid
Corticosteroid